Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Prism Pharmaceuticals
King Of Prussia, Pennsylvania, United Statesprismpharma.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
Prism Pharmaceuticals was a specialty pharmaceutical company focused on developing and commercializing acute care injectable products for cardiovascular indications. Its lead product, NEXTERONE (amiodarone hydrochloride), received FDA approval. The company was acquired by Baxter International, after which it ceased independent operations.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Investors included Baxter InternationalEW Healthcare PartnersHealthCare Royalty PartnersPaul Capital Partners
Beyond the preview
Go deeper on Prism Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prism Pharmaceuticals.